Semaglutide effect on Furosemide & Rosuvastatin PK in healthy subjects
Research type
Research Study
Full title
A trial investigating the effect of oral semaglutide on the pharmacokinetics of furosemide and rosuvastatin in healthy subjects
IRAS ID
206377
Contact name
Muna Albayaty
Contact email
Sponsor organisation
Novo Nordisk A/S
Eudract number
2015-003908-23
Duration of Study in the UK
0 years, 6 months, 3 days
Research summary
Oral semaglutide is an investigational drug that is being developed by Novo Nordisk for the treatment of type 2 diabetes mellitus (T2DM), a chronic disease where insulin-producing cells in the body are not able to produce enough insulin, or when the insulin produced by the body does not work properly. Semaglutide has been administered to over 1200 clinical trial participants.
This clinical trial is a phase 1, open-label, healthy volunteer, drug-drug interaction study that will look at how the drug levels of furosemide and rosuvastatin in the body are affected by oral semaglutide and a compound called SNAC (sodium N-(8-2-hydroxybenzoyl)amino)). SNAC is able to increase the way the body absorbs (takes into the blood stream) semaglutide. The study will also look at the safety and tolerability of oral semaglutide when given with rosuvastatin and furosemide. 36 healthy participants are expected to complete the trial.
REC name
London - Brent Research Ethics Committee
REC reference
16/LO/1890
Date of REC Opinion
25 Nov 2016
REC opinion
Further Information Favourable Opinion